Centre of Hepatology, Gastroenterology and Dietetics, Clinic of Gastroenterology, Nephrourology and Surgery, Faculty of Medicine, Vilnius University, Lithuania.
Med Sci Monit. 2012 Mar;18(3):PH28-35. doi: 10.12659/msm.882511.
The aim of this study was to assess risk factors for HCV acquisition and prevalence of anti-HCV in the general population of Lithuania.
MATERIAL/METHODS: The study enrolled 1528 randomly selected adults from the 5 biggest cities of Lithuania and its rural regions. Screening for anti-HCV was performed by analysis of peripheral capillary blood with lateral flow immunochromatography and confirmation of positive cases by peripheral venous blood testing with 2-step chemiluminescent microparticle immunoassay.
Anti-HCV prevalence in Lithuania is 2.78% and according to the standard European population the adjusted anti-HCV rate is 2.85%. It is more prevalent among men (crude rates: 4.02% males vs. 1.49% females, p=.0030) and this does not depend on age. Vilnius and Kaunas regions have higher infection rates than smaller rural regions (2.92% and 3.01% vs. 2.24%, 0.74% and 1.35%). Nowadays among our population HCV infection spreads mainly via intravenous drug use (OR=42.5, p<.0001). HCV transmission occurs through blood transfusions (OR=6.4, p=.0002), tooth removal (OR=4.1, p=.0048), childbirth (OR=5.0, p=.0224), multiple and a long-term hospitalization (OR=3.0, p=.0064), tattooing (OR=4.4, p=.0013), open traumas (OR=3.7, p=.0009) and intrafamilially (OR=11.3, p=.0002).
2.78% of the population is anti-HCV-positive. The anti-HCV rate is higher in Vilnius and Kaunas in comparison with other regions. HCV spreads mainly through intravenous drug use, but intrafamilial and some nosocomial routes are also important. The anti-HCV prevalence did not depend on age. Despite active prevention of nosocomial HCV transmission, the incidence of HCV infection does not decrease due to virus spread mostly in "trusted networks" of intravenous drug users.
本研究旨在评估立陶宛普通人群中 HCV 感染的风险因素和抗 HCV 流行率。
材料/方法:该研究招募了来自立陶宛 5 个最大城市及其农村地区的 1528 名随机成年人。通过侧流免疫层析法分析外周毛细血管血筛查抗 HCV,并用两步化学发光微粒子免疫分析法对外周静脉血检测阳性病例进行确认。
立陶宛的抗 HCV 流行率为 2.78%,根据标准欧洲人群调整后的抗 HCV 率为 2.85%。男性中更为普遍(粗率:男性 4.02% vs. 女性 1.49%,p=.0030),且与年龄无关。维尔纽斯和考纳斯地区的感染率高于较小的农村地区(2.92%和 3.01% vs. 2.24%和 0.74%)。目前,在我们的人群中,HCV 感染主要通过静脉内药物使用传播(OR=42.5,p<.0001)。HCV 通过输血(OR=6.4,p=.0002)、拔牙(OR=4.1,p=.0048)、分娩(OR=5.0,p=.0224)、多次和长期住院(OR=3.0,p=.0064)、纹身(OR=4.4,p=.0013)、开放性创伤(OR=3.7,p=.0009)和家庭内(OR=11.3,p=.0002)传播。
2.78%的人群抗 HCV 阳性。与其他地区相比,维尔纽斯和考纳斯的抗 HCV 率更高。HCV 主要通过静脉内药物使用传播,但家庭内和一些医院内途径也很重要。抗 HCV 流行率与年龄无关。尽管积极预防医院内 HCV 传播,但由于 HCV 主要在静脉内药物使用者的“信任网络”中传播,感染发病率并未降低。